Literature DB >> 22017745

Elevated gamma-glutamyltransferase is associated with mortality in lung transplantation for cystic fibrosis.

Alexander Wree1, Lars P Bechmann, Nevitha Kumarasamy, Urte Sommerwerck, Christoph Jochum, Heinz Jakob, Hideo A Baba, Guido Gerken, Markus Kamler, Ali Canbay.   

Abstract

Cystic fibrosis (CF) is a life-threatening autosomal recessive hereditary disease, affecting multiple organs. In end stage disease, lung transplantation improves the quality of life and prolongs survival. CF liver disease (CFLD) as co-morbidity develops in 8-17% of CF patients. We aimed to investigate the impact of liver injury on prognosis following lung transplantation. Thirty-one patients with CF who underwent double lung transplantation (DLTx) from 1999 to 2009 were included. Post-transplant survival, liver serum parameters as well as INR, creatinine and the MELD-Score were determined preoperatively, 1 day and 4 weeks postoperatively. Prognostic impact of liver function on outcome was analysed. Mean patient age was 25 (15-38) and post-transplant 1 year-survival was 74%, 3 years 71% and 5 years 68%. Patients were grouped according to post-transplant survival, those deceased within the first year as group I (n = 8) and patients who survived longer as group II (n = 23). Group I exhibited significantly elevated gamma-glutamyltransferase (GGT), bilirubin and reduced platelets postoperatively. Low platelet count, increased bilirubin and GGT were associated with mortality after DLTx. Prospective studies are needed to determine a potential use and clinical implications for liver function tests in patients with CF before lung transplantation.
© 2011 The Authors. Transplant International © 2011 European Society for Organ Transplantation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22017745     DOI: 10.1111/j.1432-2277.2011.01376.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  1 in total

Review 1.  [Liver dysfunctions in intensive care patients--consequences for the treatment of invasive Candida infections].

Authors:  A E Canbay; A Glöckner
Journal:  Med Klin Intensivmed Notfmed       Date:  2013-06-26       Impact factor: 0.840

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.